This is an excerpt from a member-only article. To read the article in its entirety, please login or subscribe.

NIOSH seeks to separate handling guidance from list of hazardous drugs

PRINT THIS PAGE | RETURN TO ARTICLE

July 18, 2020

by A.J. Plunkett (aplunkett@decisionhealth.com)

The CDC’s National Institute for Occupational Safety and Health (NIOSH) is proposing to separate out and expand guidance for healthcare facilities on the handling of hazardous drugs.

The proposal is part of a long-awaited update to the “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings,” which has not been updated since 2016. An update proposed for 2018 never materialized.

The newest proposal was published in the Federal Register on May 1, with a request for public comments through June 30.

The proposed rule includes a name change and reorganization of drug lists so that not all antineoplastic drugs, most often associated with cancer treatments, are grouped together. The list would be more simply the “NIOSH List of Hazardous Drugs in Healthcare Settings, 2020.”

The newest proposal was published in the Federal Register on May 1, with a request for public comments through June 30.



This is an excerpt from a member-only article. To read the article in its entirety, please login or subscribe.



Copyright © 2020. Hospital Safety Center.